HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.

Abstract
The trial CICL670AUS04 was a single-arm, open-label study of the cardiac efficacy of 18 months of deferasirox monotherapy [1]. Cardiac response in this study was related to the degree of liver siderosis. Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. In this letter, we report 2-year data in those patients who completed a 6-month extension phase (N 5 10). Cardiac and liver iron improved steadily during the 24-month period, with final cardiac T2* and LIC improving 37% and 27%, respectively, in this cohort. Serum ferritin and LVEF were not statistically different at anytime-point. When the extension phase (18-24 months) was considered in isolation, serum ferritin, liver iron concentration, and left ventricular ejection fraction were nearly identical to 18 month results. Despite this, cardiac T2* continued to trend higher, increasing 12.7% from 9.5 ms to 10.7 ms (P 5 0.06). Thus defersirox continued to demonstrate cardiac efficacy in patients with mild to moderate hepatic siderosis throughout 2 years of therapy.
AuthorsJohn C Wood, Tara Glynos, Alexis Thompson, Patricia Giardina, Paul Harmatz, Barinder P Kang, Carole Paley, Thomas D Coates
JournalAmerican journal of hematology (Am J Hematol) Vol. 85 Issue 10 Pg. 818-9 (Oct 2010) ISSN: 1096-8652 [Electronic] United States
PMID20799360 (Publication Type: Clinical Trial, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Ferritins
  • Deferasirox
Topics
  • Benzoates (therapeutic use)
  • Cardiomyopathies (drug therapy, etiology)
  • Chelation Therapy
  • Deferasirox
  • Ferritins (analysis)
  • Follow-Up Studies
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Liver Diseases (drug therapy, etiology)
  • Siderosis (drug therapy, etiology)
  • Stroke Volume
  • Transfusion Reaction
  • Treatment Outcome
  • Triazoles (therapeutic use)
  • beta-Thalassemia (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: